Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research.
Dive Brief:
- An RNA drug from Novartis and Ionis Pharmaceuticals failed to reduce the risk of heart attacks, strokes and death in a clinical trial, an outcome that could fuel doubt about an emerging way to protect cardiovascular health.
- Called pelacarsen, the drug is designed to sharply lower levels of a protein particle — known as lipoprotein(a), or “Lp(a)” — that scientific research has linked to heart disease. But in a multiyear Phase 3 study of more than 8,000 participants, a combination of pelacarsen and standard medications didn’t lower the risk of major cardiovascular events when compared to those typical therapies and a placebo.
- Novartis didn’t provide specific details in a Friday statement. They’ll be presented at an upcoming medical meeting. The company did, however, note that the negative results occurred even though pelacarsen dropped levels of Lp(a) in treated participants. “These are not the results we hoped for,” but could “help inform future approaches to cardiovascular management,” said Chief Medical Officer Shreeram Aradhye, in the statement
Dive Insight:
High cholesterol and fat levels have long been linked to a higher risk of heart problems, making treatments that can reduce them mainstays of cardiovascular care.
Genetic and epidemiological studies have shown a similar tie between Lp(a) — a fatty, cholesterol-carrying protein particle — and heart disease. According to the American Heart Association, about 20% of people have high levels of Lp(a) and, as a result, are more likely to have harmful plaques accumulate in their arteries. But they can’t lean on diet or exercise to alter their Lp(a) counts, and physicians don’t often test for the protein because there aren’t medications that can help.
Several large pharmaceutical companies have been racing to address that problem by bringing forth a new crop of therapies able to plunge Lp(a) levels in one way or another. Pelacarsen was the most advanced among these, making Novartis and Ionis’ trial one of the most eagerly anticipated in cardiovascular medicine.
Novartis had a lot riding on the outcome, too, as pelacarsen is one of a handful of prospects it hopes might offset a wave of patent expirations for key products. Analysts at William Blair estimated $6 billion in peak annual U.S. sales alone if the drug were to succeed in clinical testing.
The negative results revealed Friday, then, raise questions about this approach’s impact on cardiovascular health, and suggest there’s “meaningful risk” in other ongoing trials, wrote William Blair’s Myles Minter, in a Friday research note.
In an earlier trial, pelacarsen decreased Lp(a) levels in study participants by as much as 80% after 24 weeks, Minter noted. While the companies didn’t provide specifics, the reductions observed with the latest study were “in the range previously observed,” Minter’s team wrote after speaking with Ionis management.
There might be an opportunity for approaches with “deeper Lp(a) inhibition,” he added. Companies such as Eli Lilly, Amgen and Silence Therapeutics are advancing drugs that use different methods to stop genes from making Lp(a) particles, or block their formation. Amgen’s drug plummeted Lp(a) by more than 95% in mid-stage testing.
The study details will be crucial in gauging the potential for other medicines to perform better. In a separate note, Jefferies analyst Dennis Ding wrote that his team will be paying close attention to “any correlation” between Lp(a) levels at the start of the study, the magnitude of Lp(a) reduction and the associated clinical benefit. They’ll also keep a close eye on how close pelacarsen came to succeeding, as well as the statistical impact from patients who didn’t complete the trial.
“This will be an important dataset to dig into,” Ding wrote.
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Researcher at Russian plague laboratory dies of ‘unknown’ infection
Russian authorities have imposed "anti-epidemic measures" after a laboratory worker at an institute in Siberia dedicated to studying the plague and other infectious diseases died of a mysterious illness. The researcher, a 28-year-old female [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
A Surprising Brain Signal Could Explain Why Eating Less Protein Extends Lifespan
A new paper suggests that limiting protein intake triggers a coordinated response throughout the body that may help explain how protein restriction affects healthy aging. Animals respond to protein restriction, or reduced protein in [...]
Back and shoulder surgery is often worse than useless
Millions of operations should be scrapped SIX IN TEN Britons have surgery at some point. So do lots of Americans, at a cost of perhaps $500bn a year, a third of all spending on [...]
Cocaine plays with mind, hijacks brain circuit, drives increasingly rigid and repetitive behavior
Researchers have found that cocaine hijacks brain circuit, which to drive increasingly rigid and repetitive behavior. The brain circuit that normally participates in selecting natural mouth and face movements, but which becomes disproportionately engaged [...]
Injectable nanodevices could provide effective treatment for drug-resistant glioblastoma
The brain cancer glioblastoma is one of the most aggressive and treatment-resistant cancers known to medicine, carrying a median survival of just 12-15 months, even with the best available care. Now, researchers at the [...]
New Treatment Cuts “Bad” Cholesterol in Half for a Full Year
A single infusion of an experimental CRISPR-Cas9 therapy was reported to safely lower LDL cholesterol by 52.5% and triglycerides by 47.8%, as measured 12 months after treatment. What if one infusion could keep cholesterol [...]
Too Much RNA Can Drain a Cell’s Energy, Scientists Discover
A virus may cripple a cell’s power supply simply by producing too much of a molecule the cell needs to survive. New research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences [...]
West African scientists warn of weakening health systems and urge stronger outbreak detection
LOME, Togo (AP) — West African laboratory scientists called on governments Friday to strengthen capacity to detect disease outbreaks to avoid another major outbreak, saying health systems across the region are becoming weaker. Participants [...]
A Little-Known Protein Could Point to a New Way To Treat Alzheimer’s
A study suggests that increasing SORLA protein levels could help treat Alzheimer’s disease and other disorders involving tau protein. Increasing SORLA, a protein with a protective role in the brain, helped mice withstand damage [...]
Cancer’s Hidden Antioxidant Shield Helps It Escape the Immune System
Blocking an antioxidant protein that tumors use to suppress immune attacks improved cancer immunotherapy responses in mice. Cancer cells can release antioxidants that interfere with the immune cells trying to kill them. Researchers have [...]
Scientists Find a Berry Compound That Helps Muscle Cells Burn Fat
Pterostilbene, a compound found naturally in some foods, affects how skeletal muscles process fats by stabilizing a protein called PPARδ and increasing its signaling activity. Pterostilbene, a natural compound found in blueberries, grapes, and [...]
Two Hidden Forces Help Build the Human Brain Before Birth
Scientists have uncovered two surprising forces that help guide how the human brain forms before birth. Before birth, the human brain is shaped in large part by an unusual class of stem cells known [...]
Researchers Uncover a Hidden Trigger Behind Chronic Inflammation
The findings offer new insights that could help guide the development of future therapies. A protein called human resistin may help flip on one of the immune system’s most powerful inflammatory switches. Researchers at [...]
Scientists Have Uncovered Previously Hidden Microbial Activity on Human Skin
The most abundant microbes on your skin may not be the ones doing most of the work. Human skin supports vast communities of bacteria, fungi, and viruses that can influence its protective barrier, immune [...]
Brazilian Tree Compounds Fight COVID-19 on Multiple Fronts
Scientists found compounds in a Brazilian tree that hit SARS-CoV-2 on multiple fronts, revealing a promising new lead in the search for COVID-19 treatments. Researchers have found that galloylquinic acids extracted from the leaves [...]
